Method: IHC
Detects the CD117 (c-KIT) protein marker on tumour cells. This marker is essential for identifying gastrointestinal stromal tumours (GIST) and some other cancers, and determines eligibility for targeted drugs like imatinib.
CD117-positive GIST tumours respond dramatically to targeted therapy (imatinib/gleevec). This test confirms diagnosis and treatment eligibility — potentially life-saving information.
No preparation needed — performed on biopsy or surgical tissue.
Price (MRP)
NPR 3,200
Order as a gift© 2026 Aashirbad Care. All rights reserved.